以IL-2在体内激活LAK细胞:联合疗法展望

• 作 者: Sosman JA 杨友竹
• 出 处: 国外医学(肿瘤学分册)
• 发表日期: 1990年04期
• 关键词: 联合疗法 LAK细胞 嵌合抗体 免疫效应 免疫细胞 杂交抗体 单克隆抗体 自然杀伤细胞 细胞因子 抗癌治疗

体外或体内给予白细胞介素-2(IL-2)能激活多种涉及 T 淋巴细胞和自然杀伤细胞(NK)的免疫效应功能。这些免疫细胞及其分泌的细胞因子在宿主抗肿瘤反应中起着重要作用。单独使用较低剂量 IL-2疗法已使一小部分病人肿瘤明显缩小。临床前研究表明,IL-2与其他疗法联用可增强体内淋巴因子激活性杀伤细胞(LAK)效能;与其他细胞因子及单克隆抗体联用显示很有希望。嵌合抗体及双特异性杂交抗体的应用可能使 IL-2与抗体联合疗法更加有效。通过进一步研究,IL-2可能成为更为有效的抗癌治疗方案的组成部分。

In vitro or in vivo administration of interleukin-2 (IL-2) activates a variety of immune effector functions involving T lymphocytes and natural killer (NK) cells. These immune cells and their secreted cytokines play an important role in host anti-tumor response. The use of lower doses of IL-2 alone has resulted in a significant reduction of tumor size in a small percentage of patients. Preclinical studies have shown that IL-2 in combination with other therapies enhances the efficacy of lymphokine-activated killer cells (LAKs) in vivo, and is promising with other cytokines and monoclonal antibodies. The use of chimeric and bispecific hybrid antibodies may make IL-2 and antibody combination therapies more effective. IL-2 may be part of a more effective anti-cancer regimen after further research.